Potential barriers to the use of anti‐obesity medications in persons with spinal cord injuries and disorders

This study explores the perspectives of healthcare providers (HCPs) regarding the use of anti-obesity medications (AOMs) in individuals with spinal cord injuries and disorders (SCI/D). The research identifies key barriers that HCPs perceive as hindering the use of AOMs in this specific population. The study highlights concerns about potential side effects of AOMs, such as gastrointestinal issues, bowel problems, and skin breakdown, which could be exacerbated in individuals with SCI/D. Additionally, HCPs worry that AOMs might contribute to poor eating habits and a reliance on medication rather than adopting healthy lifestyle choices. The research also points out challenges related to the accessibility, availability, and administration of AOMs, as well as a general lack of evidence and clinical agreement on their use in the SCI/D population. The study emphasizes the need for further research to understand the interaction of AOMs with chronic conditions associated with SCI/D and to build evidence for safe and effective use.

• 1
  HCPs identified AOM side effects (bowel problems, gastrointestinal distress, skin breakdown, muscle loss) as significant barriers due to potential exacerbation in SCI/D patients.
• 2
  Concerns were raised about AOMs contributing to poor eating habits, with individuals possibly relying on medication instead of making healthy dietary choices.
• 3
  Limited availability, accessibility, and administration challenges were noted, along with a lack of evidence and clinical agreement regarding AOM use in the SCI/D population.